Hormonal
Elevated baseline plasma copeptin levels independently predict the future development of microalbuminuria, even after adjusting for incident diabetes and hypertension.
High copeptin levels are associated with an increased risk of microalbuminuria, an early sign of kidney and cardiovascular damage, independent of diabetes and high blood pressure. This suggests that vasopressin system dysregulation directly impacts kidney health. Managing weight and blood sugar may help mitigate this risk.
Apart from predicting DM and abdominal obesity, elevated copeptin signals increased risk of microalbuminuria. Interestingly, the association between copeptin and later microalbuminuria was independent of both prevalent and incident DM and hypertension.
Why this rating
Same high-quality prospective cohort design, but microalbuminuria was only measured at follow-up, limiting analysis of progression.
Source
Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort
Sofia Enhörning et al. · International Journal of Obesity · 2012
DOI 10.1038/ijo.2012.88
More from this paper
- Elevated baseline plasma copeptin levels independently predict the future development of type 2 diabetes and abdominal obesity, suggesting a primary role for the vasopressin system in cardiometabolic risk.Good
- Elevated baseline plasma copeptin levels do NOT independently predict the development of the full metabolic syndrome cluster, despite predicting its individual components (DM and abdominal obesity).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →